DE602004008773T2 - 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten - Google Patents

2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten Download PDF

Info

Publication number
DE602004008773T2
DE602004008773T2 DE602004008773T DE602004008773T DE602004008773T2 DE 602004008773 T2 DE602004008773 T2 DE 602004008773T2 DE 602004008773 T DE602004008773 T DE 602004008773T DE 602004008773 T DE602004008773 T DE 602004008773T DE 602004008773 T2 DE602004008773 T2 DE 602004008773T2
Authority
DE
Germany
Prior art keywords
amino
propyl
phenyl
aminopyridin
hydroxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004008773T
Other languages
German (de)
English (en)
Other versions
DE602004008773D1 (de
Inventor
Alan Daniel Sandwich Brown
Charlotte Alice Louise Sandwich LANE
Russell Andrew Sandwich LEWTHWAITE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE602004008773D1 publication Critical patent/DE602004008773D1/de
Application granted granted Critical
Publication of DE602004008773T2 publication Critical patent/DE602004008773T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602004008773T 2003-06-04 2004-06-01 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten Expired - Fee Related DE602004008773T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312832 2003-06-04
GBGB0312832.9A GB0312832D0 (en) 2003-06-04 2003-06-04 2-amino-pyridine derivatives useful for the treatment of diseases
PCT/IB2004/001850 WO2004108676A1 (en) 2003-06-04 2004-06-01 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamine derivatives as beta 2-adrenoceptors agonists

Publications (2)

Publication Number Publication Date
DE602004008773D1 DE602004008773D1 (de) 2007-10-18
DE602004008773T2 true DE602004008773T2 (de) 2008-01-10

Family

ID=9959308

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004008773T Expired - Fee Related DE602004008773T2 (de) 2003-06-04 2004-06-01 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten

Country Status (18)

Country Link
EP (1) EP1633715B1 (https=)
JP (1) JP2006526613A (https=)
AR (1) AR044475A1 (https=)
AT (1) ATE372321T1 (https=)
BR (1) BRPI0410946A (https=)
CA (1) CA2527788A1 (https=)
CL (1) CL2004001366A1 (https=)
DE (1) DE602004008773T2 (https=)
ES (1) ES2291882T3 (https=)
GB (1) GB0312832D0 (https=)
GT (1) GT200400116A (https=)
MX (1) MXPA05012840A (https=)
NL (1) NL1026329C2 (https=)
PA (1) PA8604301A1 (https=)
PE (1) PE20050628A1 (https=)
TW (1) TW200524603A (https=)
UY (1) UY28339A1 (https=)
WO (1) WO2004108676A1 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2322525B1 (en) 2006-04-21 2013-09-18 Novartis AG Purine derivatives for use as adenosin A2A receptor agonists
PL2035004T3 (pl) * 2006-06-09 2013-01-31 Parion Sciences Inc Podstawione fenylem pirazynoiloguanidynowe blokery kanału sodowego o aktywności beta-agonistycznej
EP2077262A4 (en) 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
DE102008049675A1 (de) 2008-09-30 2010-04-01 Markus Dr. Heinrich Verfahren zur Herstellung von 3-Aminobiphenylen
ES2442343T3 (es) 2008-12-30 2014-02-11 Pulmagen Therapeutics (Inflammation) Limited Compuestos de sulfonamida para el tratamiento de trastornos respiratorios
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
CA2220399A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
EP1078924B1 (en) * 1999-07-23 2004-10-20 Pfizer Products Inc. Intermediates and a process for producing beta-adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0217225D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
EP1556034B1 (en) * 2002-10-11 2008-04-16 Pfizer Limited Indole derivatives as beta-2 agonists

Also Published As

Publication number Publication date
PE20050628A1 (es) 2005-08-30
PA8604301A1 (es) 2004-12-16
WO2004108676A1 (en) 2004-12-16
NL1026329C2 (nl) 2005-07-26
GT200400116A (es) 2005-03-03
AR044475A1 (es) 2005-09-14
CA2527788A1 (en) 2004-12-16
BRPI0410946A (pt) 2006-06-27
MXPA05012840A (es) 2006-02-13
GB0312832D0 (en) 2003-07-09
JP2006526613A (ja) 2006-11-24
ES2291882T3 (es) 2008-03-01
EP1633715A1 (en) 2006-03-15
ATE372321T1 (de) 2007-09-15
NL1026329A1 (nl) 2004-12-07
EP1633715B1 (en) 2007-09-05
DE602004008773D1 (de) 2007-10-18
TW200524603A (en) 2005-08-01
UY28339A1 (es) 2005-01-31
CL2004001366A1 (es) 2005-05-06

Similar Documents

Publication Publication Date Title
DE602004008773T2 (de) 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten
DE602004011513T2 (de) 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
DE602005001929T2 (de) Sulfonamidderivate zur behandlung von krankheiten
EP1730103B1 (en) Formamide derivatives useful as adrenoceptor
DE60320439T2 (de) INDOLDERIVATE ALS ß2-AGONISTEN
DE602005002930T2 (de) Sulfonamidderivate zur behandlung von krankheiten
EP1624868B1 (en) "(2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)- propyl]phenyl derivatives as beta2 agonists
US20040229904A1 (en) Compounds useful for the treatment of diseases
WO2005092861A1 (en) Quinolinone derivatives pharmaceutical compositions containing them and their use
NL1028599C2 (nl) Verbindingen voor de behandeling van ziekten.
WO2005092841A1 (en) Compounds having beta-agonist activity
JP2007529499A (ja) β2受容体アゴニストとしてのフェニルアミノエタノール誘導体
EP1730141B1 (en) Compounds for the treatment of diseases
EP1577291A1 (en) Phenylethanolamine derivatives as beta-2 agonists
US7375100B2 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
JP4054366B2 (ja) 疾患の治療のために有用な化合物
EP1574501A1 (en) Quinolinone derivatives, pharmaceutical compositions containing them and their use
JP4819770B2 (ja) アドレナリン受容体として有用なホルムアミド誘導体
HK1096379A1 (zh) 用於治疗疾病的磺酰胺衍生物
HK1096379B (en) Sulfonamide derivatives for the treatment of diseases
KR20070026425A (ko) 질환 치료용 화합물

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee